公开(公告)号：JPH09189699A

公开(公告)日：1997-07-22

申请号：JP29293396

申请日：1996-11-05

Applicant: TORAY INDUSTRIES

Inventor： NAKANO HIROHISA ,  KINOSHITA YOSHIRO ,  KONO HAJIME

IPC: G01N33/543 ,  G01N1/10

Abstract: PROBLEM TO BE SOLVED: To perform automation by enabling to efficiently remove impurities present in a sample without being accompanied by the reduction in recovering ratio of the sample particle by a method other than centrifugal separation. SOLUTION: A reaction mixture in which a sample is immunologically reacted with a reagent is put in a vessel 1 having a filter part formed of a microfilter 2 together with washing liquid, and the operation applying a reduced pressure to the discharge side of the filter part to filtrate the washing liquid and the operation of newly supplying the washing liquid to the vessel 1 are repeater. Preferably, in the middle of the filtering operation, the operation of intermittently or continuously renewing the filter surface of the microfilter 2 is performed.

公开(公告)号：JPH04258287A

公开(公告)日：1992-09-14

申请号：JP2004791

申请日：1991-02-13

Applicant: TORAY INDUSTRIES

Inventor： KONO HAJIME ,  KOJIMA SHUNJI

IPC: C12N9/02

Abstract: PURPOSE:To industrially produce high-purity luciferase of Cypridina hilgendorfi. CONSTITUTION:A culture solution of gene recombinant obtained by integrating luciferase of Cypridina hilgendorfi into a gene is purified by one or more kinds of chromatographies elected from ion exchange chromatography, hydrophobic chromatography and affinity chromatography.

公开(公告)号：JPH04235198A

公开(公告)日：1992-08-24

申请号：JP12392591

申请日：1991-05-28

Applicant: TORAY INDUSTRIES

Inventor： UCHIUMI JUN ,  SHIMAZU TSUNEO ,  KONO HAJIME

IPC: A61K38/00 ,  A61K38/21 ,  A61K49/00 ,  C07K1/00 ,  C07K14/00 ,  C07K14/48 ,  C07K14/485 ,  C07K14/495 ,  C07K14/505 ,  C07K14/52 ,  C07K14/525 ,  C07K14/53 ,  C07K14/54 ,  C07K14/555 ,  C07K14/565 ,  C07K14/745 ,  C12N15/09 ,  C12N15/12 ,  C12N15/22 ,  C12P21/02 ,  C12R1/19

Abstract: PURPOSE:To add a saccharide chain biosynthetically by subjecting a physiologically active polypeptide such as human interferon beta to amino acid residue conversion and introducing a saccharide bond site. CONSTITUTION:A polypeptide obtained by converting X or Y or physiologically active polypeptide containing a partial sequence (X and Y shows amino acids except Asn) of X-Y-Ser, Thr-Ser or Thr into asparagine. In using a polypeptide or protein having physiological activity as a medicine or a diagnosticum, stability in blood can be increased, signal action enhanced, intake in target cells and target organs promoted. Consequently, medicinal effects can be increased, a dose reduced and side effects lightened.

公开(公告)号：JPS6451078A

公开(公告)日：1989-02-27

申请号：JP20861787

申请日：1987-08-21

Applicant: TORAY INDUSTRIES

Inventor： HANADA KEIZO ,  KONO HAJIME

IPC: C12N1/20 ,  C12R1/19

Abstract: PURPOSE:To obtain a synthetic medium for the production of useful protein using E.coli and its transformant, containing plural components such as L- aspartic acid, L-lysine, L-isoleucine and L-threonine and capable of effectively growing E.coli without inhibiting the proliferation of the cell. CONSTITUTION:The objective medium contains two or more components selected from L-aspartic acid, L-lysine, L-isoleucine and L-threonine. The concentration of each component such as L-aspartic acid is preferably 1mg/l-10g/l.

公开(公告)号：JPH0827200A

公开(公告)日：1996-01-30

申请号：JP16522394

申请日：1994-07-18

Applicant: TORAY INDUSTRIES

Inventor： SUZUKI EIJI ,  UEDA HIROSHI ,  KAZAMI JUN ,  KONO HAJIME

IPC: G01N33/53 ,  C07K14/195 ,  C07K14/41 ,  C07K14/435 ,  C07K16/00 ,  C07K19/00 ,  C12N9/02 ,  C12N15/09 ,  C12P21/02 ,  C12Q1/66 ,  C12Q1/68 ,  C12R1/91 ,  G01N33/535

Abstract: PURPOSE:To obtain a fused protein capable of being simply mixed with IgG to label the IgG and useful as a labeled enzyme used for luminescent immunoassay methods, etc., by binding a peptide containing an IgG-recognizing region to the end of Cypridina luciferase by a genetic engineering method. CONSTITUTION:The new fused protein capable of being simply mixed with IgG to label the IgG with Cypridina luciferase without requiring a chemical treatment for the labeling and useful as a labeling enzyme for luminescent immunoassay methods is obtained by binding a peptide containing a region recognizing the IgG Fc part of a protein A originated from Staphylococcus aureus, a peptide containing a region recognizing the IgG Fc part of a protein C originated from a streptococcus, etc., to the amino end of the Cypridina luciferase. The fused protein is obtained by expressing a vector which is produced by binding the gene of a peptide having a region recognizing the IgG to the 5'-site of Cypridina luciferase gene through a linker.

公开(公告)号：JPH05176787A

公开(公告)日：1993-07-20

申请号：JP18248791

申请日：1991-07-23

Applicant: TORAY INDUSTRIES

Inventor： HANADA KEIZO ,  SANO EMIKO ,  NARUTO MASANOBU ,  KONO HAJIME

IPC: C12P21/00 ,  C12R1/91

Abstract: PURPOSE:To obtain a natural type interleukin-6 with good productivity by culturing a cell capable of producing the interleukin-6 and treating the cultured cell with a DNA synthesis inhibitor. CONSTITUTION:A cell capable of producing interleukin-6 (IL-6) is cultured in a Roux jar, etc. When the cell becomes confluent, cytokinin preferably at a low unit is incubated and treated with an inducer and a DNA synthesis inhibitor (preferably 0.1ng to 5mug/ml mitomycin C is added within 2 days before, simultaneously or within 2 days after the addition of the inducer) to afford the objective interleukin-6.

公开(公告)号：JPH0954090A

公开(公告)日：1997-02-25

申请号：JP21070595

申请日：1995-08-18

Applicant: TORAY INDUSTRIES

Inventor： MATSUMORI AKIRA ,  KONO HAJIME ,  IDA NOBUO ,  NAKAMURA HARUJI

IPC: G01N33/53 ,  A61K39/395 ,  G01N33/535

Abstract: PROBLEM TO BE SOLVED: To perform diagnosis on acute myocardial infarction, or the like, by utilizing a specific antibody for a monocytic chemotactic and activating factor(MCAF) in measuring the MCAF. SOLUTION: Anti-MCAF antibody, i.e., a monoclonal antibody, is fixed to a support, such as a microplate, a microbead, or a magnetic microbead. A sample is reacted with the fixing support, and an unreacted reaction solution is separated. Next, another antibody which differs in the place of recognition of an antigen is used, an enzyme-labeled antibody is added and reacted, and an unreacted reaction solution is separated. An enzyme substrate is added, an enzyme reaction product after the reaction is measured, and the concentration of a MCAF in the sample is measured from a calibration curve prepared in advance using a standard MCAF of a known concentration. Therefore, factors that may lead to abnormal accumulation of monocytes/macrophages and activation can be measured for the advantage of diagnosis on acute myocardial infarction, etc.

公开(公告)号：JPH08154699A

公开(公告)日：1996-06-18

申请号：JP29843294

申请日：1994-12-01

Applicant: TORAY INDUSTRIES

Inventor： MURAO YASUO ,  KONO HAJIME ,  OSHIHARA WATARU

IPC: C12Q1/66

Abstract: PURPOSE: To obtain the subject solution, containing a cypridinoid luciferin and an acidic solute, capable of enhancing the stability of an aqueous solution of the cypridinoid luciferin, improved in luminous efficiency and stability of measured values and useful for a high-sensitivity sensing system, etc., for an enzyme immunoassay. CONSTITUTION: A cypridinoid luciferin and an acidic salute such as formic, propionic, malic, tartaric, ethylenediaminetetraacetic or citric acid are dissolved in a 10mM phosphoric acid buffer physiological saline solution, etc., at pH

公开(公告)号：JPH02196798A

公开(公告)日：1990-08-03

申请号：JP1807389

申请日：1989-01-26

Applicant: TORAY INDUSTRIES

Inventor： UCHIUMI JUN ,  KONO HAJIME

IPC: G01N33/50 ,  A61K38/00 ,  A61P9/10 ,  A61P9/14 ,  A61P17/00 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/435 ,  C07K14/52 ,  C12P21/00 ,  C12R1/91

Abstract: NEW MATERIAL:A protein as growth factor of vascular endothelial cell adsorbing to heparin-immobilizing gel and able to be eluted with >=0.8M sodium chloride, having 38,000-48,000 molecular weight in non-reductive condition and 4.0-5.0, 5.5-7.0 and 8.5-9.0 isoelectric points. USE:Curing accelerator of heat injury and wound, remedy agent of angiopathy or diagnostics and remedy agent of malignant tumor or chronic rheumatism, etc. PREPARATION:For instance, human diploid fibroblast is cultured in a medium and supernatant solution of said fibroblast is collected and concentrated, then resultant concentrated solution is flowed through heparin-agarose column, concentration of sodium chloride in 200mM acetic acid buffer solution (pH4.5) is gradually increased, thus adsorbed substance is eluted from the column at >=0.8M sodium chloride concentration and the eluate is introduced into reverse-phase column chromatography and purified to afford the aimed growth factor of vascular endothelial cell.

公开(公告)号：JPH01222782A

公开(公告)日：1989-09-06

申请号：JP4815088

申请日：1988-02-29

Applicant: TORAY INDUSTRIES

Inventor： HANADA KEIJI ,  OOTANI MIE ,  KONO HAJIME

IPC: C12N9/99 ,  A61K38/55 ,  A61P27/02 ,  A61P27/14 ,  A61P29/00 ,  A61P37/08 ,  C07K1/22 ,  C07K14/435 ,  C07K14/81

Abstract: PURPOSE:To accomplish mass purification collagenase inhibitor in high purity, by contacting a collagenase inhibitor solution with a red coloring matter-linked carrier or blue coloring matter-linked carrier to effect eluation. CONSTITUTION:A collagenase inhibitor solution is brought into contact, at pH5-10 (pref. 7-9), with a red or blue coloring matter-linked carrier to effect adsorption. Thence, said inhibitor is eluated from the carrier; where, the eluation process is determined by the pH value and ionic strength of the eluating agent, the rate of a hydrogen bond-weakening substance such as glycerin and so on [e.g., the eluation is made in an alkaline region (pH7-9)]. Said red or blue coloring matter-linked carrier may be used singly or in combination. A second column may be combined, in this case, a cation exchange column is preferable.